GSK Ends Camlipixant Program for Chronic Cough After Split Phase III Outcome
GSK sits 42% above its 52-week low of $35.45.
Summary
Camlipixant failed in one of two Phase III chronic cough trials and missed secondary endpoints, prompting GSK to halt development. The IBS program remains active.
Key Events · Product Development and Regulatory · GSK
-
Mixed Phase III Results
CALM-1 met its primary endpoint, with camlipixant 50mg BID delivering a statistically significant reduction in 24-hour cough frequency at week 12. However, CALM-2 did not reach statistical significance for the same endpoint at week 24, and the 25mg dose failed in both studies.
-
Secondary Endpoints Missed
Key secondary endpoints, including a Chronic Cough Diary measure, did not meet target thresholds in either trial, undermining the clinical relevance of the primary endpoint win.
-
RCC Program Discontinued
Citing limited efficacy unlikely to transform patient care, GSK decided not to progress further development of camlipixant in refractory chronic cough. Results will be published for scientific contribution.
-
IBS Program Continues
The Phase IIb BALANCE trial evaluating camlipixant in irritable bowel syndrome (IBS-D and IBS-M) will continue, preserving a potential path for the asset.
Analysis · GSK · Life Sciences
Camlipixant, a P2X3 antagonist aimed at refractory chronic cough, produced a split decision across two pivotal trials. While CALM-1 hit its primary endpoint on cough frequency, CALM-2 missed, and key secondary endpoints fell short in both studies. Management judged the efficacy insufficient to transform patient care and is discontinuing the RCC program. This removes a late-stage asset in a disease with no approved therapies, though the IBS program continues. For a $105B pharma giant, the financial impact is modest, but the read-through to pipeline execution matters after recent oncology and RSV wins.
At the time of this filing, GSK was trading at $50.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.6B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.